Recent reports indicate that President Donald Trump was persuaded to delay an announcement regarding a pivotal shift in U.S. drug policy. The proposed change involves reclassifying cannabis from a Schedule I to a Schedule III substance, a significant alteration with numerous implications for the marijuana industry.
Trump’s Seismic Drug Policy Shift
The drug policy change was initiated following extensive lobbying efforts and contributions from key figures in the marijuana sector. Notably, Trump met with Kim Rivers, the CEO of Trulieve, a prominent Florida-based cannabis company, alongside confidante Howard Kessler and Florida Sheriff Gordon Smith in early December.
Attempted Early Announcement
During the meeting, Trump expressed a desire to announce the decision on his platform, Truth Social. However, those present urged him not to reveal the information prematurely. There was a sense of urgency and tension as advisors intervened, explaining that a formal process needed to be followed, including a mandatory 30-day waiting period.
According to Sheriff Smith, the chaotic scene illustrated the weight of the moment. “It was surreal,” he remarked, reflecting on the pushback from staff trying to restrain Trump from making an untimely public announcement.
Official Confirmation of the Policy Change
On December 18, 2025, Trump signed an executive order officially reclassifying marijuana, marking the end of its Schedule I status, which had persisted since the Controlled Substances Act was enacted in 1970. This classification placed cannabis alongside drugs like heroin and cocaine, categorizing it as having no accepted medical use and a high potential for abuse.
Political Implications and Reactions
- The move defied the views of many Republicans who regard marijuana as a “gateway drug.”
- Speaker of the House Mike Johnson expressed his concerns during the meeting, underscoring the political divide on drug policy.
This significant reclassification has the potential to reshape attitudes, regulations, and the legal landscape for marijuana across the United States. With ongoing discussions surrounding drug policy reform, this change marks a noteworthy moment in U.S. history.
